Vaxxinity is a clinical-stage biotech developing a new class of immunotherapy medicines for chronic diseases. The company has no approved products and no revenue. Vaxxinity's core thesis is that monoclonal antibodies (mAbs) — the standard treatment for many chronic diseases — are effective but too expensive and too burdensome to administer for most patients. Vaxxinity aims to replicate the therapeutic effects of mAbs using active immunotherapy: vaccines that train a patient's own immune system to produce the relevant antibodies, at a lower cost and with simpler dosing (quarterly injections rather than frequent IV infusions). The underlying technology is the AIM Platform, a synthetic peptide-based vaccine platform licensed from related-party United Biomedical. Vaxxinity's lead programs target Alzheimer's disease (UB-311, which has completed Phase 2a with encouraging but preliminary efficacy signals), Parkinson's disease (UB-312, Phase 1 complete), high cholesterol via PCSK9 inhibition (VXX-401, Phase 1 ongoing), and migraine prevention (UB-313, deprioritized). Vaxxinity also has a COVID-19 booster vaccine (UB-612) with regulatory submissions pending in the UK and Australia. Vaxxinity retains worldwide rights to all candidates and outsources manufacturing entirely to CMOs. The company funds operations through equity raises and has disclosed substantial doubt about its ability to continue as a going concern, with the timing of key trials dependent on securing additional capital or a partnership.